H Schulze

560 total citations
18 papers, 355 citations indexed

About

H Schulze is a scholar working on Epidemiology, Genetics and Immunology. According to data from OpenAlex, H Schulze has authored 18 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 10 papers in Genetics and 7 papers in Immunology. Recurrent topics in H Schulze's work include Inflammatory Bowel Disease (10 papers), Microscopic Colitis (8 papers) and Biosimilars and Bioanalytical Methods (6 papers). H Schulze is often cited by papers focused on Inflammatory Bowel Disease (10 papers), Microscopic Colitis (8 papers) and Biosimilars and Bioanalytical Methods (6 papers). H Schulze collaborates with scholars based in Germany and Switzerland. H Schulze's co-authors include Axel Dignaß, Heinz Döbeli, Dietrich Stüber, Gerda Huber, Hanno Langen, Franz Hartmann, Niels Teich, Jürgen M. Stein, Andreas Stallmach and Carsten Schmidt and has published in prestigious journals such as Gastroenterology, Journal of Neurochemistry and Alimentary Pharmacology & Therapeutics.

In The Last Decade

H Schulze

14 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H Schulze Germany 7 199 165 95 74 71 18 355
Gabrielle Boucher Canada 11 191 1.0× 88 0.5× 208 2.2× 155 2.1× 99 1.4× 19 500
Julie Wassell United Kingdom 7 110 0.6× 83 0.5× 145 1.5× 38 0.5× 78 1.1× 9 341
Kazuhiko Sugawara Japan 5 93 0.5× 53 0.3× 96 1.0× 114 1.5× 66 0.9× 11 333
D. Piancatelli Italy 14 47 0.2× 73 0.4× 62 0.7× 272 3.7× 48 0.7× 43 478
Suzanne K. Cordovado United States 11 155 0.8× 42 0.3× 93 1.0× 59 0.8× 62 0.9× 23 391
Shinichiro Yokota United States 13 59 0.3× 148 0.9× 164 1.7× 183 2.5× 196 2.8× 33 582
Andrea Fuhrer Switzerland 6 92 0.5× 52 0.3× 124 1.3× 96 1.3× 62 0.9× 11 433
M. van Eygen Belgium 12 135 0.7× 33 0.2× 134 1.4× 24 0.3× 47 0.7× 14 365
Jean‐Paul Soulillou France 12 105 0.5× 62 0.4× 131 1.4× 176 2.4× 160 2.3× 17 523

Countries citing papers authored by H Schulze

Since Specialization
Citations

This map shows the geographic impact of H Schulze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Schulze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Schulze more than expected).

Fields of papers citing papers by H Schulze

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H Schulze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Schulze. The network helps show where H Schulze may publish in the future.

Co-authorship network of co-authors of H Schulze

This figure shows the co-authorship network connecting the top 25 collaborators of H Schulze. A scholar is included among the top collaborators of H Schulze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H Schulze. H Schulze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Teich, Niels, et al.. (2024). P625 Electronic patient-reported outcomes in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional German LISTEN II study. Journal of Crohn s and Colitis. 18(Supplement_1). i1192–i1192. 1 indexed citations
2.
Teich, Niels, H Schulze, J. Knop, Michael Obermeier, & Andreas Stallmach. (2021). Novel Approaches Identifying Relevant Patient-Reported Outcomes in Patients With Inflammatory Bowel Diseases—LISTEN 1. Crohn s & Colitis 360. 3(3). otab050–otab050. 10 indexed citations
3.
Stein, Jürgen M., et al.. (2020). Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn’s disease. United European Gastroenterology Journal. 8(7). 804–813. 28 indexed citations
4.
Schulze, H, et al.. (2018). A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scandinavian Journal of Gastroenterology. 53(6). 670–676. 28 indexed citations
5.
Berger, C, et al.. (2018). P717 Comparison of two different techniques to assess vedolizumab trough levels in adult patients with IBD. Journal of Crohn s and Colitis. 12(supplement_1). S474–S474. 1 indexed citations
6.
Schulze, H, et al.. (2017). P521 A prospective cohort study to assess the relevance of Vedolizumab drug level monitoring in IBD patients. Journal of Crohn s and Colitis. 11(suppl_1). S344–S345.
7.
8.
Berger, C, et al.. (2017). P474 An enzyme-linked immunosorbent assay for therapeutic drug monitoring of vedolizumab. Journal of Crohn s and Colitis. 11(suppl_1). S320–S320. 1 indexed citations
9.
Schmidt, Carsten, Raja Atreya, Tony Bruns, et al.. (2017). P326 Efficacy of vedolizumab on patient-reported outcomes in ulcerative colitis patients: results from a prospective German observational study. Journal of Crohn s and Colitis. 11(suppl_1). S242–S243. 1 indexed citations
10.
Schulze, H, et al.. (2017). A Prospective Cohort Study to Assess the Relevance of Vedolizumab Drug Level Monitoring in IBD Patients. Gastroenterology. 152(5). S753–S753. 5 indexed citations
11.
Stallmach, Andreas, Raja Atreya, Tony Bruns, et al.. (2016). Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Alimentary Pharmacology & Therapeutics. 44(11-12). 1199–1212. 118 indexed citations
12.
Schulze, H, et al.. (2014). Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Alimentary Pharmacology & Therapeutics. 40(9). 991–1008. 37 indexed citations
13.
Schulze, H, et al.. (2007). Start des EU-Projekts DRUID / The start of the EU-project DRUID. 53(1). 1 indexed citations
14.
Albrecht, Moritz H., et al.. (2007). Suchtmittel im Strassenverkehr - Zahlen und Fakten. 1 indexed citations
15.
Mathias, K., et al.. (1998). High-flow-Priapismus nach stumpfem perinealem Trauma. Der Radiologe. 38(8). 710–713. 6 indexed citations
16.
17.
Bichler, K.-H., et al.. (1980). Nachweis harnstoffspaltender Keime im Urin bei Steinpatienten. Urologia Internationalis. 35(6). 421–426. 3 indexed citations
18.
Schulze, H. (1954). [Experience with the treatment by means of vagal ganglion block with special reference to non-specific intestinal toxicosis].. PubMed. 22(1-2). 95–100. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabrielle Boucher Breakdown of academic impact, for papers by Julie Wassell Breakdown of academic impact, for papers by Kazuhiko Sugawara Breakdown of academic impact, for papers by D. Piancatelli Breakdown of academic impact, for papers by Suzanne K. Cordovado Breakdown of academic impact, for papers by Shinichiro Yokota Breakdown of academic impact, for papers by Andrea Fuhrer Breakdown of academic impact, for papers by M. van Eygen Breakdown of academic impact, for papers by Jean‐Paul Soulillou
Rankless by CCL
2026